Last reviewed · How we verify
Prostacyclin Receptor Agonist
At a glance
| Generic name | Prostacyclin Receptor Agonist |
|---|---|
| Sponsor | Actelion |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Patient-Reported Outcomes and Adherence After Transition From Inhaled Iloprost to Oral Selexipag in Pulmonary Arterial Hypertension
- A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist (PHASE1)
- Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
- Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHASE4)
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) (PHASE3)
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PHASE2)
- A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prostacyclin Receptor Agonist CI brief — competitive landscape report
- Prostacyclin Receptor Agonist updates RSS · CI watch RSS
- Actelion portfolio CI